Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes.
Hofman J, Sorf A, Vagiannis D, Sucha S, Kammerer S, Küpper JH, Chen S, Guo L, Ceckova M, Staud F. Hofman J, et al. Mol Pharm. 2019 Nov 4;16(11):4436-4450. doi: 10.1021/acs.molpharmaceut.9b00361. Epub 2019 Oct 21. Mol Pharm. 2019. PMID: 31633365
Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo.
Vagiannis D, Budagaga Y, Morell A, Zhang Y, Novotná E, Skarka A, Kammerer S, Küpper JH, Hanke I, Rozkoš T, Hofman J. Vagiannis D, et al. Among authors: hofman j. Int J Mol Sci. 2021 Nov 3;22(21):11936. doi: 10.3390/ijms222111936. Int J Mol Sci. 2021. PMID: 34769363 Free PMC article.
Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter.
Vagiannis D, Zhang Y, Budagaga Y, Novotna E, Skarka A, Kammerer S, Küpper JH, Hofman J. Vagiannis D, et al. Among authors: hofman j. Toxicol Appl Pharmacol. 2022 Jan 1;434:115823. doi: 10.1016/j.taap.2021.115823. Epub 2021 Dec 9. Toxicol Appl Pharmacol. 2022. PMID: 34896433
332 results